Photo Credit: by Cnordic Nordic, Pexels.com
Chronic obstructive pulmonary disease, or COPD, is a long-term lung disease that can make everyday life harder in ways healthy lungs do not. According to Mayo Clinic, the symptoms of COPD, including shortness of breath, chronic cough, mucus, wheezing, frequent lung infections, fatigue, and others, can all wear people down over time. For many patients, maintenance inhalers are a core part of treatment because they help control symptoms and lower the risk of flare-ups that can lead to urgent care visits, hospital stays, and worsening lung function.
But for patients and caregivers, treatment is not just about what works in theory; it is also about what is realistic month after month. An inhaler only helps if you can afford to refill it and keep taking it as prescribed. That is why the question of which COPD inhaler matters so much. Fluticasone furoate/vilanterol trifenatate (Breo Ellipta) vs. fluticasone/salmeterol (Advair) is a choice you might face. Both are established maintenance inhalers used in COPD care, but they differ in dosing, device design, side effects, and, most importantly for many households, long-term cost.
What Is COPD and Why Do Maintenance Inhalers Matter?
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease that commonly includes emphysema (a long-term lung condition that causes shortness of breath), chronic bronchitis (an inflammation of the lining of your bronchial tubes, leading to coughing up thickened mucus), or both. According to Mayo Clinic, it is caused by damage to the lungs and causes trouble breathing, a daily cough that brings up mucus, a tight, whistling sound in the lungs called wheezing, and other symptoms. These COPD symptoms can suddenly worsen during exacerbations, sometimes called flare-ups or flares.
The most essential step to treating COPD is quitting smoking; however, medications are also used. Inhalers used for COPD generally fall into two broad categories: rescue inhalers and maintenance inhalers. Rescue inhalers are for quick symptom relief when breathing suddenly gets worse. Maintenance inhalers are taken regularly, usually every day, to help keep symptoms under control and reduce future problems. According to their patient information, fluticasone furoate/vilanterol trifenatate (Breo Ellipta) and fluticasone/salmeterol (Advair) are maintenance inhalers used for long-term control, not rescue inhalers for sudden shortness of breath. Long-term, affordability really matters because COPD treatment only works well when people can stay on it consistently. If a medication is too expensive, some patients may skip doses, delay refills, or stop treatment altogether. That can lead to poorer symptom control and more exacerbations. In real life, the best long-acting inhaler is the one that provides good disease control at a price you can sustain.
Breo Ellipta vs. Advair: What’s the Difference?
Breo Ellipta contains two active ingredients: fluticasone furoate, an inhaled corticosteroid, and vilanterol, a long-acting beta agonist. For COPD, the approved Breo Ellipta strength is 100 mcg/25 mcg taken once daily. It is delivered through the Ellipta dry powder inhaler device. You open the cover, inhale the dose, close it, and then rinse your mouth without swallowing. One key point to know is that if the cover is opened and closed without inhaling, that dose is lost.
Advair contains fluticasone propionate, also an inhaled corticosteroid, plus salmeterol, another long-acting beta agonist. For COPD, the standard approved dose is 250 mcg/50 mcg twice daily, roughly 12 hours apart. The Advair Diskus version is a dry powder inhaler device, which has a few more steps than the Ellipta. The device is opened, a lever is clicked to load the dose, you inhale, and then close it. There is also an aerosol inhaler version of Advair called hydrofluoroalkane (HFA) (although this version is typically used in cases of asthma). In this case, you press and inhale the spray. After both, you rinse your mouth without swallowing.
Both inhalers are combination inhaled corticosteroid (ICS)/long-acting beta agonist (LABA) products, which reduce inflammation and help keep airways open over time. Neither should be used for sudden breathing problems. Both also require regular daily use to provide their full benefit.
The right medication for you is the one you and your healthcare provider select based on your individual health needs.
Cost Comparison: Breo Ellipta vs. Brand and Generic Advair
This is where the biggest practical difference appears.
Typically, fluticasone furoate/vilanterol (Breo Ellipta) remains the more expensive option for many patients because it does not have the same generic competition that fluticasone/salmeterol (Advair) does. GoodRx lists Breo Ellipta at an average retail price of about $407. (Actual prices vary by pharmacy, location, and discount program.)
By contrast, generic fluticasone/salmeterol products, the generic equivalent category for Advair’s drug combination, can be much cheaper. GoodRx lists fluticasone/salmeterol at an average retail price of around $326. That difference from brand-only Breo pricing is the main reason Advair-type treatment is often the more budget-friendly choice for long-term COPD management.
Brand Advair itself may still cost more than the generic, but generic availability changes the entire conversation. Once lower-cost alternatives enter the market, many patients no longer need to rely on the brand product to get the same medication combination. Over a year of treatment, that can add up to hundreds or even thousands of dollars in savings, depending on the patient’s insurance and pharmacy.
Advair and Breo Ellipta Availability
Breo Ellipta and multiple versions of Advair are available from Canadian Pharmacy King.
Breo Ellipta (fluticasone furoate/vilanterol trifenatate)
• Breo Ellipta is manufactured by GlaxoSmithKline in Canada and the United Kingdom and is also marketed as Relvar Ellipta.
• It is available in strengths of 100 mcg/25 mcg (equivalent to 92 mcg/22 mcg delivered dose) and 200 mcg/25 mcg (equivalent to 184 mcg/22 mcg delivered dose), with each inhaler containing 30 doses.
• It is available from US$136.63.
Advair Diskus (fluticasone furoate/vilanterol trifenatate)
• Advair Diskus is manufactured by GlaxoSmithKline in Canada and may also be supplied from Australia, India, New Zealand, or the United Kingdom.
• It is available in strengths of 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg, with each inhaler containing 60 doses.
• It is available from US$57.54.
Fluticasone furoate/vilanterol trifenatate (generic of Advair Diskus, commonly known as Seroflo)
• Generic fluticasone furoate/vilanterol trifenatate is supplied by India and Canada.
• It is available in strengths of 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg, with each inhaler containing 60 doses.
• It is available from US$82.29.
Advair HFA (inhaler) (fluticasone furoate/vilanterol trifenatate)
• Advair HFA is manufactured by GlaxoSmithKline in Canada, New Zealand, or Turkey, and is also marketed as the Seretide MDI Inhaler (Evohaler).
• It is available in strengths of 125 mcg/25 mcg and 250 mcg/25 mcg, with each inhaler containing 120 doses.
• It is available from US$107.32.
Insurance Coverage and Copays
Insurance can reduce what patients actually pay, but it does not always eliminate the difference between these inhalers.
In general, generics are more likely to be placed on lower insurance tiers, which usually means lower copays. Brand-only medications are more likely to land on higher tiers or require higher coinsurance. Formularies and tiers determine what people pay, and when a generic becomes available, the brand medication may move to a more expensive tier. That is one reason generic fluticasone/salmeterol often remains the better value even for insured patients.
Which Inhaler Is Easier to Use?
Ease of use matters more than many people realize. An inhaler that is technically more expensive may still be more cost-effective for a specific person if it is easier to use correctly and easier to remember.
Brand name Breo Ellipta (furoate/vilanterol trifenatate) has two convenience advantages. First, it is taken once daily, not twice daily. Second, the Ellipta device is relatively simple. That may sound like a small difference, but simpler routines can lead to better long-term adherence, and better long-term adherence can lead to better health overall.
Generic fluticasone/salmeterol or brand name Advair Diskus is taken twice daily and involves a few more device steps. Many patients use it successfully, but a twice-daily schedule is naturally easier to miss than a once-daily schedule. Research on inhaler adherence has found that once-daily regimens are generally associated with better adherence than twice-daily regimens in those with asthma and COPD. That means Breo Ellipta may offer an indirect value advantage for some people, especially if they struggle with remembering evening doses.
That does not automatically make furoate/vilanterol trifenatate the more cost-effective option overall. It just means that the lowest pharmacy price is not the only number that matters. If you miss doses on fluticasone/salmeterol but reliably take furoate/vilanterol trifenatate every day, the more expensive inhaler may still provide better real-world value for you.
Side Effects and Safety Warnings to Know
Furoate/vilanterol trifenatate (Breo Ellipta) and fluticasone/salmeterol (Advair) share many side effects because they both combine an inhaled corticosteroid with a long-acting beta agonist.
Common side effects with Breo Ellipta in COPD include upper respiratory infection, headache, cough, oral yeast infection (candidiasis), back pain, joint pain, bronchitis, sinus inflammation, pneumonia, and others, according to its prescribing information. Bone mineral density and eye health should be assessed throughout treatment. This medication may not be the best choice for people with cardiovascular disorders because of beta-adrenergic stimulation. More prescribing information can be found here.
Common side effects with Advair in COPD include oral yeast infection (candidiasis), pneumonia, viral respiratory infections, headache, throat irritation, hoarseness and voice changes, and muscle and bone pain. Similar to Breo Ellipta, bone mineral density and eye health should be assessed throughout treatment with Advair. Reduced adrenal function (adrenal insufficiency) can also occur. More prescribing information can be found here.
Both inhalers can also cause paradoxical bronchospasm, cardiovascular effects such as increased heart rate in some people, and steroid-related risks such as reduced bone density, adrenal suppression, cataracts, and glaucoma in susceptible patients. Because both include an inhaled corticosteroid, rinsing the mouth after every dose is important to help reduce the risk of an oral yeast infection.
For many patients, the side effect profiles are similar enough that cost and convenience become the deciding factors. Still, preference for a specific device should be discussed with a healthcare provider before making a switch.
Which COPD Inhaler Is the Better Value?
For most patients looking strictly at long-term affordability, fluticasone/salmeterol usually comes out ahead because a generic is available and much cheaper than brand-only furoate/vilanterol trifenatate. That makes generic fluticasone/salmeterol COPD therapy the better budget choice for many uninsured patients, high-deductible patients, and people whose insurance places furoate/vilanterol trifenatate on a higher insurance tier.
But value is not exactly the same as the lowest price.
Brand name Breo Ellipta may make sense for patients who:
• Have strong insurance coverage for it
• Qualify for savings assistance
• Struggle with adherence and do better with once-daily dosing
• Find the Ellipta device easier to use than the Diskus
Generic fluticasone/salmeterol treatment for COPD may make more sense for patients who:
• Are uninsured
• Have high deductibles
• Need the lowest possible ongoing monthly cost
• Are comfortable with twice-daily dosing and the Diskus-style device
In other words, the most cost-effective inhaler depends on both the pharmacy price and the patient’s real-life ability to stay on therapy.
The Bottom Line
Furoate/vilanterol trifenatate (Breo Ellipta) and fluticasone/salmeterol (Advair) are both established maintenance inhalers for COPD, and both can help with long-term symptom control when used appropriately. But when the focus is long-term affordability, Advair usually has the advantage because generic fluticasone/salmeterol products can dramatically reduce out-of-pocket costs. Breo Ellipta’s main strengths are once-daily dosing and a simple inhaler device, not a lower price.
If cost is making it hard to stay on treatment, do not simply stretch doses or stop the inhaler on your own. Talk with your doctor, pharmacist, or COPD care team. A generic switch, a different pharmacy, a mail-order option, or a discount program may help you find a treatment plan that is both medically effective and financially sustainable.
Sources
1. De Keyser, H., Vuong, V., Kaye, L. et al. (2023). Is once versus twice daily dosing better for adherence in asthma and chronic obstructive pulmonary disease? The Journal of Allergy and Clinical Immunology in Practice, 11(7), 2087-2093.e3. https://doi.org/10.1016/j.jaip.2023.03.053
2. GlaxoSmithKline. (2019). Patient Information: Advair Diskus. GSK. Retrieved April 13, 2026, from https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Advair_Diskus/pdf/ADVAIR-DISKUS-PIL-IFU.PDF
3. GlaxoSmithKline. (2023). Highlights of Prescribing Information. GSK. Retrieved April 13, 2026, from https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Breo_Ellipta/pdf/BREO-ELLIPTA-PI-PIL-IFU.PDF
4. Mayo Clinic Staff. (2026, March 13). COPD. Mayo Clinic. Retrieved April 9, 2026, from https://www.mayoclinic.org/diseases-conditions/copd/symptoms-causes/syc-20353679
5. S. Vergnaud. (2026, February 24). A Guide to COPD Inhalers. GoodRx. Retrieved April 13, 2026, from https://www.goodrx.com/conditions/copd/guide-to-inhalers
###